Climb Bio
CLYM
21 hedge funds and large institutions have $46.2M invested in Climb Bio in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
2% more capital invested
Capital invested by funds: $45.5M → $46.2M (+$685K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 61.14% → 61.14% (-0%)
9% less funds holding
Funds holding: 23 → 21 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$37.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$16.3K |
| 3 |
Millennium Management
New York
|
+$4.63K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$415 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$74 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
-$37.3K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$14.4K |
| 3 |
Morgan Stanley
New York
|
-$4.7K |
| 4 |
BlackRock
New York
|
-$1.94K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$154 |
CLYM Hedge Fund Activity: Q1 2024 in Review
21 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2024, worth a combined $46.2M — up 1.5% from $45.5M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CLYM and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was BML Capital Management, adding an estimated $37.8K. The largest seller was Cerity Partners, exiting entirely with an estimated $37.3K sold.
- 21 institutional investors held Climb Bio (CLYM) as of Q1 2024, down from 23 in Q4 2023.
- Funds reported $46.2M of Climb Bio stock for Q1 2024, up 1.5% quarter-over-quarter.
- 1 fund opened new Climb Bio positions in Q1 2024 and 3 closed out, a net change of -2 holders.
- The largest Climb Bio buyer in Q1 2024 was BML Capital Management, an estimated $37.8K added.
- The largest Climb Bio seller in Q1 2024 was Cerity Partners, an estimated $37.3K sold.
Based on aggregated 13F filings for Q1 2024.